Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct

British Journal of Cancer

Volumn 92, Issue 8, 2005, Pages 1421-1429

  Roth, A ^a   Rohrbach, F ^b   Weth, R ^b   Frisch, B ^a   Schuber, F ^a   Wels, W S ^b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Cancer vaccines; ErbB2; HER2; Lipopeptide; Liposomes; Renal cell carcinoma

Indexed keywords

ADJUVANT; CANCER VACCINE; CD8 ANTIGEN; CHOLESTEROL; CYTOTOXIC T LYMPHOCYTE EPITOPE [63-71]; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; HEMAGGLUTININ; LIPOPEPTIDE; LIPOSOME; PEPTIDE; PEPTIDE HA[307-319]; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CANCER INHIBITION; CELLULAR IMMUNITY; CONJUGATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG POTENCY; DRUG SPECIFICITY; FEMALE; HELPER CELL; KIDNEY CARCINOMA; LUNG NODULE; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SPLEEN CELL; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HEMAGGLUTININS, VIRAL; HUMANS; KIDNEY NEOPLASMS; LIPOSOMES; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; PEPTIDES; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 18944394124     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602526     Document Type: Article

References (53)

1. Alving CR, Koulchin V, Glenn GM, Rao M (1995) Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev 145: 5-31
2. Alving CR, Wassef NM (1994) Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation. AIDS Res Hum Retroviruses 10: S91-S94
3. Andrieu M, Desoutter JF, Loing E, Gaston J, Hanau D, Guillet JG, Hosmalin A (2003) Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells. J Virol 77: 1564-1570
4. Bergers JJ, ten Hagen TL, van Etten EW, Bakker-Woudenberg IA (1995) Liposomes as delivery systems in the prevention and treatment of infectious diseases. Pharm World Sci 17: 1-11
5. Bessler WG, Cox M, Lex A, Suhr B, Wiesmuller KH, Jung G (1985) Synthetic lipopeptide analogs of bacterial lipoprotein are potent polyclonal activators for murine B lymphocytes. J Immunol 135: 1900-1905
6. Bessler WG, Jung G (1992) Synthetic lipopeptides as novel adjuvants. Res Immunol 143: 548-553
7. Boeckler C, Dautel D, Schelte P, Frisch B, Wachsmann D, Klein JP, Schuber F (1999) Design of highly immunogenic liposomal constructs combining structurally independent B cell and T helper cell peptide epitopes. Eur J Immunol 29: 2297-2308
8. Boeckler C, Frisch B, Schuber F (1998) Design and synthesis of thiol-reactive lipopeptides. Bioorg Med Chem Lett 8: 2055-2058
9. Bohlen P, Stein S, Dairman W, Udenfriend S (1973) Fluorometric assay of proteins in the nanogram range. Arch Biochem Biophys 155: 213-220
10. Bourgeois C, Tanchot C (2003) CD4 T cells are required for CD8 T cell memory generation. Eur J Immunol 33: 3225-3231
11. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L, Brugger W (1998) Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58: 732-736
12. Campion K, Ding W, Yan Z, Ozawa H, Seiffert K, Miranda E, Lonati A, Beissert S, Granstein RD (2000) Tumor antigen presentation by dermal antigen-presenting cells. J Invest Dermatol 115: 57-61
13. Chikh G, Schutze-Redelmeier MP (2002) Liposomal delivery of CTL epitopes to dendritic cells. Biosci Rep 22: 339-353
14. Deres K, Schild H, Wiesmuller KH, Jung G, Rammensee HG (1989) In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 342: 561-564
15. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16-20
16. Fernandes I, Frisch B, Muller S, Schuber F (1997) Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen. Mol Immunol 34: 569-576
17. Finn OJ (2003) Cancer vaccines: between the idea and the reality. Nat Rev Immunol 3: 630-641
18. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109-2117
19. Gahery-Segard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, Tartar A, Levy JP, Gras-Masse H, Guillet JG (2000) Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 74: 1694-1703
20. Hertz CJ, Kiertscher SM, Godowski PJ, Bouis DA, Norgard MV, Roth MD, Modlin RL (2001) Microbial lipopeptides stimulate dendritic cell maturation via Toll-like receptor 2. J Immunol 166: 2444-2450
21. Jäger E, Jäger D, Knuth A (2002) Clinical cancer vaccine trials. Curr Opin Immunol 14: 178-182
22. Knutson KL, Schiffman K, Cheever MA, Disis ML (2002) Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 8: 1014-1018
23. Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107: 477-484
24. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N, Schuler G (1996) High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184: 741-746
25. Kono K, Rongcun Y, Charo J, Ichihara F, Celis E, Sette A, Appella E, Sekikawa T, Matsumoto Y, Kiessling R (1998) Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 78: 202-208
26. Li WM, Dragowska WH, Bally MB, Schutze-Redelmeier MP (2003) Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 21: 3319-3329
27. Machy P, Serre K, Baillet M, Leserman L (2002) Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains. J Immunol 168: 1172-1180
28. Maurer-Gebhard M, Schmidt M, Azemar M, Altenschmidt U, Stöcklin E, Wels W, Groner B (1998) Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells. Cancer Res 58: 2661-2666
29. Murphy GP, Hrushesky WJ (1973) A murine renal cell carcinoma. J Natl Cancer Inst 50: 1013-1025
30. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K, Nakamura H, Kanematsu T, Shiku H (1997) Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159: 1336-1343
31. O'Sullivan D, Sidney J, Del Guercio MF, Colon SM, Sette A (1991) Truncation analysis of several DR binding epitopes. J Immunol 146: 1240-1246
32. Okugawa T, Ikuta Y, Takahashi Y, Obata H, Tanida K, Watanabe M, Imai S, Furugen R, Nagata Y, Toyoda N, Shiku H (2000) A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur J Immunol 30: 3338-3346
33. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 19: 3159-3167
34. Oussoren C, Storm G (2001) Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50: 143 -156
35. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92: 432-436
36. Piechocki MP, Ho YS, Pilon S, Wei WZ (2003) Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 171: 5787-5794
37. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R (1999) Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 163: 1037-1044
38. Rothwell SW, Wassef NM, Alving CR, Rao M (2000) Proteasome inhibitors block the entry of liposome-encapsulated antigens into the classical MHC class I pathway. Immunol Lett 74: 141-152
39. Rouser G, Fkeischer S, Yamamoto A (1970) Two dimensional thin layer Chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids 5: 494-496
40. Schelté P, Boeckler C, Frisch B, Schuber F (2000) Differential reactivity of maleimide and bromoacetyl functions with thiols: application to the preparation of liposomal diepitope constructs. Bioconj Chem 11: 118-128
41. Schild H, Deres K, Wiesmuller KH, Jung G, Rammensee HG (1991) Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol 21: 2649-2654
42. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483
43. Schuurhuis DH, Laban S, Toes RE, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EI, Rea D, Offringa R, Geuze HJ, Melief CJ, Ossendorp F (2000) Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 192: 145-150
44. Sheikh NA, al-Shamisi M, Morrow WJ (2000) Delivery systems for molecular vaccination. Curr Opin Mol Ther 2: 37-54
45. Singh M, O'Hagan DT (2002) Recent advances in vaccine adjuvants. Pharmaceut Res 19: 715-728
46. Tartour E, Ciree A, Haicheur N, Benchetrit F, Fridman WH (2000) Development of non-live vectors and procedures (liposomes, pseudoviral particles, toxin, beads, adjuvants) as tools for cancer vaccines. Immunol Lett 74: 45-50
47. Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189: 753-756
48. Uhl B, Wolf B, Schwinde A, Metzger J, Jung G, Bessler WG, Hauschildt S (1991) Intracellular localization of a lipopeptide macrophage activator: immunocytochemical investigations and EELS analysis on ultrathin cryosections of bone marrow-derived macrophages. J Leukoc Biol 50: 10-18
49. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188: 51-64
50. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R, Chesnut RW (1995) Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95: 341-349
51. Wang JC, Livingstone AM (2003) Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol 171: 6339-6343
52. Whiteside TL, Odoux C (2004) Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53: 240-248
53. Wiesmuller KH, Bessler WG, Jung G (1992) Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response. Int J Pept Protein Res 40: 255-260